MOKAN Wealth Management Inc. Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

MOKAN Wealth Management Inc. purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 18,779 shares of the biopharmaceutical company's stock, valued at approximately $1,735,000. Gilead Sciences makes up about 1.1% of MOKAN Wealth Management Inc.'s investment portfolio, making the stock its 25th biggest position.

Other hedge funds and other institutional investors have also modified their holdings of the company. AMF Tjanstepension AB raised its holdings in Gilead Sciences by 14.7% in the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company's stock worth $33,645,000 after acquiring an additional 51,390 shares during the period. Creative Planning grew its position in Gilead Sciences by 16.1% in the 3rd quarter. Creative Planning now owns 219,045 shares of the biopharmaceutical company's stock worth $18,365,000 after purchasing an additional 30,451 shares during the last quarter. Swedbank AB grew its position in Gilead Sciences by 10.2% in the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company's stock worth $171,672,000 after purchasing an additional 189,622 shares during the last quarter. nVerses Capital LLC acquired a new stake in Gilead Sciences in the 3rd quarter worth $25,000. Finally, Global Retirement Partners LLC grew its position in Gilead Sciences by 11.9% in the 3rd quarter. Global Retirement Partners LLC now owns 8,788 shares of the biopharmaceutical company's stock worth $737,000 after purchasing an additional 933 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the company's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares of the company's stock, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company's stock, valued at $7,427,227.92. The trade was a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 713,000 shares of company stock valued at $67,945,181 over the last ninety days. Insiders own 0.16% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded up $2.38 during trading on Thursday, reaching $110.03. The company had a trading volume of 7,682,796 shares, compared to its average volume of 7,382,672. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $110.11. The stock has a market cap of $137.13 billion, a PE ratio of 297.38, a PEG ratio of 0.88 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The business's 50 day moving average price is $94.70 and its 200-day moving average price is $88.23.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Analysts expect that Gilead Sciences, Inc. will post 7.94 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.87%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences's payout ratio is 832.43%.

Wall Street Analyst Weigh In

GILD has been the topic of several research analyst reports. Robert W. Baird raised their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a "neutral" rating in a research report on Thursday, November 7th. Truist Financial raised their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research report on Friday, November 8th. The Goldman Sachs Group lifted their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Mizuho lifted their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an "outperform" rating in a research report on Thursday, November 21st. Finally, Citigroup assumed coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $125.00 target price on the stock. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.